L
Lymphatica Medtech
A minimally invasive implant and a discrete wearable device designed to re-establish the lymphatic circulation
About Lymphatica Medtech
Lymphatica Medtech is a clinical-stage medical device company focused on developing solutions for lymphatic diseases, specifically chronic lymphedema. The company is working on LymphoDrain™, an active implantable lymphatic bypass system designed to alleviate the symptoms of this condition.
The system consists of a magnetically controlled micropump and catheters that are implanted subcutaneously. This device works by draining the excess lymphatic fluid that accumulates in tissues, which is characteristic of lymphedema. The minimally invasive nature of the implant is a key feature of the proposed treatment.
Lymphatica Medtech's primary market is patients suffering from chronic lymphedema, a condition that can be genetic or occur as a result of other medical treatments, such as cancer therapy. The company's business model revolves around the research, development, and eventual commercialization of its medical devices. As a clinical-stage company, it is currently focused on securing regulatory approval and conducting clinical trials to validate the safety and efficacy of its technology. The company has successfully raised capital through multiple funding rounds to support these efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Lausanne, Switzerland
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 82.8/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Chronic Disease, Non-Invasive medical devices and treatments, Spinout, Sustainable Development Goals, Wearable, Start-Up Rescue Instrument (EIT Health), Start-Up Rescue Instrument 2020 (EIT Health)
- Technology
- Hardware, Deep Tech, Connected Device
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Oct 2024 | $20M | $79M | HTGF · OCCIDENT · Panakès Partners · TechWald Holding | ↗ |
| DEBT✓Debt | Jun 2023 | $367K | — | Fondation FIT | ↗ |
Growth signals
Latest recorded traffic for Lymphatica Medtech is 1.3K monthly website visits, up 828.6% over the last three months. Lymphatica Medtech's team grew 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
European Innovation Council
MassChallenge
Innosuisse
Venture Kick
Fondation FIT
Series A9 investors entered at this stage
HTGF
EIT Health
LIVEventures
Panakès Partners
TechWald Holding
CDP Venture Capital
OCCIDENT
ZKB - Zürcher Kantonalbank
Investors' club
Other known investors4 additional known investors
CHUV - University Hospital Lausanne
EPFL Swiss Federal Polytechnic School of Lausanne
University of Lausanne
EPFL Innovation Park
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lymphatica Medtech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lymphatica Medtech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.